Immunotoxin containing a disulfide-stabilized antibody fragment

Details Immunotoxin containing a disulfide-stabilized antibody fragment Immunotoxin containing a disulfide-stabilized antibody fragment

1997-08-21

1999-11-09

Hutzell, Paula K.

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

4242361, 5303873, 5303877, A61K 39395, C07K 1600

Patent

active

059808950

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

This invention pertains to the production and use of Pseudomonas-derived immunotoxins modified to increase their toxicity and potency in therapy. In particular, the immunotoxins of this invention include a disulfide-stabilized (ds) target-binding agent, such as the variable region of an antibody molecule, and a Pseudomonas exotoxin that does not require proteolytic activation for cytotoxic activity.
Immunotoxins were initially produced by chemically coupling antibodies to toxins (Vitetta et al. Cell, 41: 653-654 (1985); Pastan et al., Ann. Rev. Biochem. 61: 331-354 (1992)) to form chimeric molecules. In these molecules, the antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing. Several toxins have been used to make immunotoxins, including ricin A chain, blocked ricin, saporin, pokeweed antiviral protein, diphtheria toxin and Pseudomonas exotoxin A (PE) (Pastan et al., Science 254: 1173-1177 (1991); Vitetta et al., Semin. Cell Biol. 2: 47-58 (1991); Tazzari et al., Br. J. Hematol. 81: 203-211 (1992); Uckun et al., Blood, 79: 2201-2214 (1992)).
Several clinical trials with immunotoxins have shown activity against lymphomas and other cancers derived from the hematopoietic system (Vitetta et al., Cancer Res. 51: 4052-4058 (1991); Grossbard et al., J. Clin. Oncol. 11: 726-737 (1993)). However, these immunotoxins are heterogeneous and their large size limits penetration into solid tumors. Second generation immunotoxins are totally recombinant molecules made by fusing the smallest functional module of an antibody, the Fv fragment, to a truncated toxin which lacks the cell-binding domain (Brinkmann et al., Proc. Natl. Acad. Sci. USA 88: 8616-8620 (1991); Kreitman et al., Blood, 80: 2344-2352 (1992)). The small size of single-chain Fv-immunotoxins makes them much more useful than chemical conjugates of whole antibodies for certain therapeutic applications because their small size increases tumor penetration and efficacy (Fukimori et al., Cancer Res. 49: 5656-5663 (1989); Jain, Cancer Res., 50: 814-819 (1990); Sung et al., Cancer Res. 50: 7382-7392 (1990)).
Several types of recombinant Fv-immunotoxins containing PE have been made and tested in vitro as well as in animal models (Brinkmann et al., Proc. Natl. Acad. Sci. USA 88: 8616-8620 (1991); Kreitman et al., Blood, 80: 2344-2352 (1992); Batra et al., Proc. Natl. Acad. Sci. USA 89: 5867-5871 (1992); Reiter et al., Cancer Res. 54: 2714-2718 (1994); Brinkmann et al., Proc. Natl. Acad. Sci. USA 90: 547-551 (1993)). Initially, the Fv regions of the immunotoxins were arranged in a single-chain form (scFv-immunotoxin) with the V.sub.H and V.sub.L domains connected by a linking peptide. More recently, disulfide-stabilized forms of Fv-immunotoxins (dsFv-immunotoxins) have been generated in which the V.sub.H and V.sub.L domains are connected by a disulfide bond engineered into the framework region (see, e.g. copending application U.S. Ser. No. 08/077,252 filed on Jun. 14, 1993; Brinkmann et al., Proc. Natl. Acad. Sci. USA 90: 7538-7542 (1993); Reiter et al., Protein Eng., 7: 697-704 (1994)). Disulfide-stabilized Fv immunotoxins are much more stable than single-chain immunotoxins and can show improved binding to antigen (Reiter et al., J. Biol. Chem. 269: 18327-18331 (1994); Reiter et al., Protein Eng. 7: 697-704 (1994)). In addition, dsfv-immunotoxins are slightly smaller in size than scfv-immunotoxins, and may exhibit better tumor penetration.
Recombinant immunotoxins containing PE must be proteolytically activated within the cell by cleavage in domain II between amino acids 279 and 280 (Ogata et al. J. Biol. Chem., 267: 25369-25401 (1992)). To eliminate the need for intracellular proteolytic activation and thereby increase cytotoxic activity, the toxin moiety of recombinant toxins has been modified. This was initially done with recombinant toxins containing TGF.alpha. by producing a truncated toxin (PE280-613) with TGF.alpha. inserted near the en

REFERENCES:
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5458878 (1995-10-01), Pastan et al.
Debinski, Waldemar, et al. (1994) "An Immunotoxin with Increased Activity and Homogeneity Produced by Reducing the Number of Lysine Residues in Recombinant Pseudomanas Exotoxin", Bioconjugate Chemistry, 5(1):40-46.
Kuan, Chien-Tsun, et al. (1996) "Improved antitumor activity of a recombinant anti-Lewis.sup.Y immunotoxin not requiring proteolytic activation", Proc. Natl. Acad. Sci. USA, 93:974-978.
Kuan, Chien-Tsun, et al. (1996) "Recombinant Immuntoxin Containing a Disulfide-Stabilized Fv Directed at erbB2 That Does Not Require Proteolytic Activation", Biochemistry, 35:2872-2877.
Theuer, Charles P., et al. (1993) "A Recombinant Form of Pseudomonas Exotoxin A Containing Transforming Growth Factor Alpha Near Its Carboxyl Terminus For The Treatment of Bladder Cancer", The Journal of Urology, 149:1626-1632.
Theuer, Charles P., et al. (1993) "Immunotoxins Made with a Recombinant Form of Pseudomonas Exotoxin A That Do Not Require Proteolysis for Activity", Cancer Research, 53:340-347.
Batra et al. Proc. Natl. Acad. Sci. USA, 89:5867-5871 (1992).
Bird et al. Science, 242:423-426 (1988).
Brinkman et al. Proc. Natl. Acad. Sci. 88:8616-8620 (1991).
Buchner et al. Anal. Biochem. 205:263-270 (1992).
Chaudhary et al. Proc. Natl. Acad. Sci. USA, 84:4538-4542 (1987).
Chaudhary et al. Proc. Natl. Acad. Sci. USA, 85:2939-2943 (1988).
Cumber et al. J. Immunol. 149(1):120-126 (1992).
Dillman et al. Ann. Internal Med. 111:592-600 (1989).
Glockshuber et al. Biochemistry, 29(6):1362-1367 (1990).
Glockshuber et al. Biochemistry, 31(5):1270-1279 (1992).
Gray et al. Proc. Natl. Acad. Sci. USA, 81:2645-2649 (1984).
Harris et al. Tibtech 11:42-44 (1993).
Heimbroook et al. Proc. Natl. Acad. Sci. USA, 87:4697-4701 (1990).
Hird et al. Chapter 17 in Genes and Cancer, Editor Carney (1990).
Huston et al., Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988).
Jinno et al. J. Biol. Chem. 264:15953-15959 (1989).
Kasprzyk et al. Cancer Res. 53:2771-2776 (1992).
Kreitman et al. Bioconjugate Chemistry, pp. 58-62 (1992).
Kreitman et al. Bioconjugate Chemistry, pp. 63-68, (1992).
Kurucz et al. Proc. Natl. Acad. Sci. 90:3830-3834 (1993).
Lorberboum-Galski et al. J. Biol. Chem. 265:16311-16317 (1990).
Lyons et al. Protein Engineering, 3:703-708 (1990).
Ogata et al. J. Biol. Chem. 265:20678-20685 (1990).
Osband et al. Immunotherapy 11(6):193-195 (1990).
Pack et al. Biochemistry 31:1579-1584 (1992).
Pantoliano et al. Biochemistry, 30:10117-10125 (1991).
Pastan et al. Science, 254:1173-1177 (1991).
Pluckthun. Immunological Reviews, 130:151-188 (1992).
Reiter et al. Biochemistry 33:5451-5459 (1994).
Reiter et al. J. Biol. Chem. 269(28):18327-18331 (1994).
Seetharam et al. J. Biol. Chem. 266:17376-17381 (1991).
Siegall et al. J. Biol Chem. 264:14256-14261 (1989).
Siegall et al. Biochemistry 30:7154-7159 (1991).
Stemmer et al. Biotechniques, 14(2):256-265 (1993).
Theuer et al. J. Biol. Chem. 267:16872-16877 (1992).
Waldmann et al. Science, 252:1657-1662 (1991).
Watson et al. in Molecular Biology of the Gene, 4th Ed., Benjamin/Cummings Publ. Co., Menlo Park, CA, p. 313 (1987).
1/Brinkman et al. PNAS, USA 90 : 7538-7542, 1993.
2/Brinkman et al. J. Immunol. 150 : 2774-2784, 1993.
3/Theuer, CP et al. Cancer Res. 53 : 340-347, 1993.
4/Chaudhary et al. PNAS, USA, 87: 308-312, 1990.
5/Benhar I et al. Bot. Eng. 7(12):1509-15, 1994.
John de Kruif, et al., "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," 232-236 Febs Letters (Dec. 16, 1996).
Yoram Reiter, et al, "Stabilization of the Fv Fragments in Recombinant Imunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," 5451-5459 Biochemistry (May 10, 1994).
Robert J. Kreitman, et al., "Pseudomonas Exoto

Affiliated with

Also associated with

Rating

Immunotoxin containing a disulfide-stabilized antibody fragment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotoxin containing a disulfide-stabilized antibody fragment , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotoxin containing a disulfide-stabilized antibody fragment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1451879